Difference between revisions of "Agomelatine-mirtazapine"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = mirtazapine  
 
| to = mirtazapine  
 
| stop =  
 
| stop =  
* Administration of agomelatine can be stopped abruptly at every dosage.
+
| stop = {{StopAgomelatine}}
| start =  
 
 
* A wash-out period is not necessary.
 
* A wash-out period is not necessary.
 
* Start administration of mirtazapine the next day in a dosage of 15 mg/day.
 
* Start administration of mirtazapine the next day in a dosage of 15 mg/day.
 
* If necessary, increase dosage of mirtazapine to 30 mg/day.
 
* If necessary, increase dosage of mirtazapine to 30 mg/day.
<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
+
 
 
}}
 
}}

Revision as of 13:42, 5 March 2010

Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine
Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine

Switch medication from agomelatine to mirtazapine.[1] [2]

Nietinrijdenbord.png Stop agomelatine
  • Day 1: Stop agomelatine.
  • Agomelatine can be stopped abruptly for every dosage.[3]
  • A wash-out period is not necessary.
  • Start administration of mirtazapine the next day in a dosage of 15 mg/day.
  • If necessary, increase dosage of mirtazapine to 30 mg/day.



  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.